Revelation Biosciences Sets 1-for-7 Reverse Split Effective October 20
REVB is trading near its 52-week low of $0.71 (7.4% above the low).
Summary
Revelation Biosciences will execute a 1-for-7 reverse stock split effective October 20, 2026, consolidating every seven shares into one. The move comes as the stock trades near $0.76 and the company carries a micro-cap valuation, with the Q2 10-Q warning of potential Nasdaq delisting under a new rule and only $11.5M in cash to fund operations through Q1 2027. A reverse split is typically a compliance maneuver to lift the share price back above Nasdaq's minimum bid threshold and avoid delisting, not a sign of improving fundamentals. The split itself does not change the company's value or cash position, but it signals the listing pressure flagged in the August filings is now being acted on. Watch whether the post-split price holds above Nasdaq's minimum bid requirement after the October 20 effective date.
At the time of this announcement, REVB was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.71 to $5.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.